GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » EV-to-Revenue

BLIS Technologies (NZSE:BLT) EV-to-Revenue : 1.54 (As of Jun. 20, 2024)


View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, BLIS Technologies's enterprise value is NZ$16.10 Mil. BLIS Technologies's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was NZ$10.48 Mil. Therefore, BLIS Technologies's EV-to-Revenue for today is 1.54.

The historical rank and industry rank for BLIS Technologies's EV-to-Revenue or its related term are showing as below:

NZSE:BLT' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.14   Med: 5.66   Max: 18.32
Current: 1.54

During the past 13 years, the highest EV-to-Revenue of BLIS Technologies was 18.32. The lowest was 1.14. And the median was 5.66.

NZSE:BLT's EV-to-Revenue is ranked better than
82.69% of 1034 companies
in the Biotechnology industry
Industry Median: 7.565 vs NZSE:BLT: 1.54

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-20), BLIS Technologies's stock price is NZ$0.019. BLIS Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was NZ$0.01. Therefore, BLIS Technologies's PS Ratio for today is 2.38.


BLIS Technologies EV-to-Revenue Historical Data

The historical data trend for BLIS Technologies's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BLIS Technologies EV-to-Revenue Chart

BLIS Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.09 6.92 5.05 2.94 1.29

BLIS Technologies Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.05 - 2.94 - 1.29

Competitive Comparison of BLIS Technologies's EV-to-Revenue

For the Biotechnology subindustry, BLIS Technologies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BLIS Technologies's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's EV-to-Revenue falls into.



BLIS Technologies EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

BLIS Technologies's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=16.099/10.484
=1.54

BLIS Technologies's current Enterprise Value is NZ$16.10 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLIS Technologies's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was NZ$10.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BLIS Technologies  (NZSE:BLT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

BLIS Technologies's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.019/0.008
=2.38

BLIS Technologies's share price for today is NZ$0.019.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Mar. 2024 was NZ$0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BLIS Technologies EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of BLIS Technologies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BLIS Technologies (NZSE:BLT) Business Description

Traded in Other Exchanges
N/A
Address
442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).

BLIS Technologies (NZSE:BLT) Headlines

From GuruFocus

Olstein Strategic Opportunities Fund 2014 Investor Letter

By Canadian Value Canadian Value 04-01-2015

Blount International Inc. (BLT) CEO Joshua L Collins buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-13-2009

John Rogers Increases Stake in Blount International

By Tiziano Frateschi Tiziano Frateschi 04-13-2015

John Rogers Trims Stake in Blount International

By Kyle Ferguson Kyle Ferguson 04-18-2016

Blount International Inc. (BLT) CEO International Inc Blount buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-01-2009

Jean-Marie Eveillard Sells More Blount International

By Holly LaFon Holly LaFon 10-09-2012